GlassScriptPhysician profile
Neeta Gaur
NPI 1770554420
$6,182.41
in general payments reported to CMS, 2019-2025
36 companies · $744 in 2025
The $744 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $426 · 2020: $438 · 2021: $661 · 2022: $595 · 2023: $808 · 2024: $2,511 · 2025: $744.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,733 · Travel and Lodging: $1,142 · Education: $188.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,733.01 |
| Travel and Lodging | $1,142.36 |
| Education | $187.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $1,459.95 | 2023-2025 | Inspire |
| Jazz Pharmaceuticals INC. | $601.60 | 2019-2025 | Xywav |
| Astrazeneca Pharmaceuticals LP | $477.28 | 2020-2025 | Breztri, Fasenra, Tezspire |
| Boehringer Ingelheim Pharmaceuticals, INC. | $452.76 | 2019-2025 | Ofev, Stiolto Respimat, Spiriva Respimat |
| Grifols USA, LLC | $359.79 | 2019-2025 | Prolastin-C Liquid |
| Genzyme Corporation | $336.57 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $334.09 | 2021-2024 | Dupixent |
| Glaxosmithkline, LLC. | $307.88 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Harmony Biosciences LLC | $302.82 | 2021-2025 | Wakix |
| Electromed, INC. | $288.17 | 2021-2025 | Smartvest |
| Inari Medical, INC. | $194.12 | 2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Genentech USA, INC. | $122.40 | 2019-2025 | Xolair |
| Amgen INC. | $98.56 | 2022-2024 | Tezspire |
| Novartis Pharmaceuticals Corporation | $86.11 | 2020-2025 | |
| Insmed, INC. | $84.88 | 2019-2025 | Arikayce |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| United Therapeutics Corporation | $68.99 | 2021-2023 | |
| Pulmonx Corporation | $61.46 | 2019-2025 | Zephyr Endobronchial Valve, Chartis Catheter, Zephyr Delivery Catheter |
| Merck Sharp & Dohme LLC | $60.10 | 2022-2023 | Recarbrio, Zerbaxa |
| Sunovion Pharmaceuticals INC. | $59.34 | 2019 | |
| Mylan Specialty L.P. | $47.35 | 2023-2024 | Yupelri |
| Baxter Healthcare | $37.51 | 2022-2024 | Hillrom - Vest System Model 105 Home Care |
| Gilead Sciences, INC. | $36.40 | 2021-2024 | |
| Mallinckrodt Hospital Products INC. | $35.48 | 2020-2022 | |
| Abbvie INC. | $31.62 | 2023 | |
| La Jolla Pharmaceutical Company | $29.38 | 2019 | |
| Philips North America LLC | $27.31 | 2024 | (7999) Src Undivided |
| Axsome Therapeutics, INC. | $25.83 | 2023 | Sunosi |
| Actelion Pharmaceuticals US, INC. | $25.81 | 2019 | |
| Vapotherm INC | $21.53 | 2021 | |
| Astellas Pharma US INC | $18.24 | 2023 | Cresemba |
| Janssen Pharmaceuticals, INC | $16.95 | 2019 | |
| Azurity Pharmaceuticals, INC. | $16.69 | 2025 | Horizant |
| Advanced Respiratory, INC | $15.75 | 2020 | |
| Verona Pharma, INC. | $15.57 | 2025 | Ohtuvayre |
| Takeda Pharmaceuticals U.S.A., INC. | $12.44 | 2020 | |
| Shire North American Group INC | $11.68 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Neeta Gaur listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.